Lorpiprazole

DB09195ApprovedSmall molecule

Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.

Mechanism: Lorpiprazole is a serotonin antagonist and reuptake inhibitor thus, its activity is performed by antagonizing the 5-HT2A and the 5-HT2C serotoninergic receptors as well as the alpha1 and alpha2 adrenergic receptors, H1 histaminergic receptors and at high doses, inhibiting the SERT serotonin transporter.
Curator reviewed · 1 reference
Primary indication: In 2016, lorpiprazole was classified in the "Chemical structure-related drug-like criteria of global approved drugs" as an antipsychotic and anxiolytic.Curator reviewed
Formula / weight: C₂₁H₂₆F₃N₅ · 405.469 g/mol (avg)

Resolves to

Compound

UNII0M14O7T47QCAS108785-69-9PubChem20055414

Structure

InChIKeyBNRMWKUVWLKDQJ-YJBOKZPZSA-NSMILES[H][C@@]12CCC[C@]1([H])C1=NN=C(CCN3CCN(CC3)C3=CC=CC(=C3)C(F)(F)F)N1C2

Targets

P28223HTR2AP28335HTR2CP35367HRH1P31645SLC6A4

What you can answer from here — as of February 21, 2021

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,167Drug interactionsStructured to mechanism, not free text

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lorpiprazole, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account